TLP
AKRO

Tri Locum Partners’s Akero Therapeutics AKRO Stock Holding History

Tri Locum Partners’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-88,524
Closed -$3.39M – 62
2023
Q1 		$3.39M Sell
88,524
-40,327
-31% -$1.8M 1.03% 27
2022
Q4 		$7.06M Sell
128,851
-80,397
-38% -$3.44M 2.86% 13
2022
Q3 		$7.13M Buy
+209,248
New +$3.2M 1.96% 20

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Tri Locum Partners's AKRO Position: Q2 2023 in Review

Tri Locum Partners sold out of Akero Therapeutics (AKRO) in Q2 2023, closing a stake of 88,524 shares — an estimated $3.39M sold.

Tri Locum Partners first reported a position in AKRO in Q3 2022 and held it in 3 quarters. The position peaked at $7.13M in Q3 2022. 157 funds tracked by Wall St. Rank hold AKRO as of Q2 2023.

  • Tri Locum Partners reported no remaining Akero Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Tri Locum Partners sold 88,524 Akero Therapeutics shares in Q2 2023, an estimated $3.39M.
  • Tri Locum Partners first reported a position in Akero Therapeutics in Q3 2022 and held it in 3 quarters.
  • Tri Locum Partners's Akero Therapeutics position peaked at $7.13M in Q3 2022.
  • 157 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2023.

Based on Tri Locum Partners's 13F filing for Q2 2023, filed 14 Aug 2023.